Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialBrian G. Feagan, Rupert W. Leong, Shihong Sheng et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 235
886: EFFICACY AND SAFETY OF COMBINATION INDUCTION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS THROUGH WEEK 12 OF THE PHASE 2A VEGA STUDYBrian G. Feagan, Julián Panés, Bruce E. Sands et al.|Gastroenterology|2022Cited by 1
S716 Induction Combination Therapy With Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-Blind, Proof-of-Concept VEGA StudyBrian G. Feagan, Julián Panés, Bruce E. Sands et al.|The American Journal of Gastroenterology|2022Cited by 1